Search

United States pharmaceutical firms have been developing DNA binding molecules that are seen to regulate gene expression. Anticancer drugs have been found to bind to guanine residues in the major grooves of DNA. Comments from researchers are also provided.

The 2010 Pittsburgh Conference on Analytical Chemistry & Applied Spectroscopy was held in Orlando, Florida from February 28, 2010 to March 5, 2010. The event showcased new products from instrument companies, which are seeing new technologies and solutions despite the economic downturn. Improvement forecasts for 2010 are discussed.

The recipients of the 2010 Arthur C. Cope Scholar Awards from the American Chemical Society are presented. These include Helen Blackwell who is recognized for her contribution to the molecule language, Christopher J. Chang for his development of metal ion and oxidation tracking tools, and John A. Gerlt for his research on enzyme reactions.

Drugmakers are increasingly testing the idea of selectively targeting RNA sites with small molecules. The various advances in this field are discussed.

There were fewer exhibitors but more attendees at the 2009 Pittsburgh Conference on Analytical Chemistry & Applied Spectroscopy as compared to the previous year's statistics. The products presented at the conference and the awards given out are discussed.

The field of synthetic biology dedicated to the engineering of new biological pathways in cells and the creation of new organisms. The field aims to use these organisms to create new products such as drugs, biofuels, and enzymes. Developments in the field and practical applications for the inventions from this field are discussed.

An overview of the 2008 Pittcon conference held in New Orleans along with a description of some new instruments that were on display is put forth.

The article highlights chemistry-based research with many developments in structural analysis.

Researchers traced parts of the life story of proteins, from their biosynthesis on ribosomes to protein folding and from their functional existence in cells to their ultimate demise from degradation during the 21st symposium of the Protein Society held in Boston.

Researchers are working hard to better understand the physiological effects of changes in biomolecular glycosylation. The understanding of glycosylation will help in devising new ways to diagnose and treat conditions that arise when glycosylation fails.

A research on g-quadruplex structure varying DNA sequences and environment is conducted. X ray crystallography was used to understand the biological function of G- quadruplexes and to guide the design of drugs.

Medicinal chemists have disclosed the structures of agents for hepatitis C, cancer, autoimmune and inflammatory conditions, incontinence and migraine headaches at the American Chemical Society national meeting in the spring 2007. The structure of the hepatitis C medication [GSK6.sub.25433], a highly potent and selective inhibitor of type 1a and 1b HCV polymerases with good activity in cell-based assays, was disclosed for the first time.

The author discusses the various drugs that were devised by the speakers at the American Chemical Society (ACS) session in their private academic laboratories. All the drugs have proven to be extremely effective and successful.

Registrations at Pittsburgh Conference on Analytical Chemistry and Applied Spectroscopy, Pittcon 2007 was 10% higher than 2006 conference probably due to the technical program of American Chemical Society (ACS) being shifted to Pittcon from the national meeting. The exhibition of new lab equipments and instruments was the main attraction.

Ribosomes are regarded as the nature's most versatile molecular protein synthesizer. Researchers have presented the detailed picture of the architecture and mechanism of the ribosome.

A broader perspective is being adopted by some mechanistic enzymologists by investigating the way enzymes work individually and also their functioning in the context of the cell. This will enable the researchers to specify the locations of different enzymes in cells, determine the substrates and protein partners with which the enzymes interact, and probe the impact of enzymes cell metabolites.

Achievements in various disciplines of chemistry, organic chemistry, carbohydrate chemistry, structural biology and chemical analysis, in the year 2006 are highlighted. Organic chemistry saw advances in both total synthesis and reaction development, researchers developed a high throughput technique for screening mutant glucosyl transferases in carbohydrate chemistry, structural biologist won a Nobel Prize in Chemistry and analytical chemistry also achieved greater heights.

Carbohydrate Chemist and Biochemists, the controlling personalities who tend to be controlling personalities who tame wild sugars on proteins and natural products, have achieved remarkable success in achieving the desired results. The different mechanisms devised by carbohydrate chemists and biochemists to control the glycosylation of a protein or natural products are presented.

Drug companies in 2006 are evaluating all phases of discovery and development and are using novel approaches to speed them up to eliminate R&D bottlenecks. A survey conducted in 2005 estimated that US biomedical research funding rose from $48 billion to $94 billion over a decade beginning in the early 1990s.

Pittcon, the Pittsburgh conference on analytical chemistry and applied spectroscopy, held its 57th meeting in Orlando in 2006, where it delivered a wide range of edifying presentations on analytical chemistry and introduced a plethora of the new analytical instruments for research and industry. The 2006 meeting saw the use of innovative technologies to develop instruments that are smaller and cheaper, offer higher performance, and are overall just better than ever before.

The progress in arrays, functional analysis, and synthetic techniques is helping in understanding the challenges posed by carbohydrates. The progress made in the field of carbohydrate is discussed.

A new spectroscopic study of protonated methane, CH5(super +) is allowing long-standing questions about the mysterious ion's structure and dynamics to be answered with greater clarity than before. CH5(super +), also called methonium ion, has resisted complete spectroscopic characterization since it was discovered in early 1950s, but researchers have obtained the first broad-frequency infrared spectrum of the ion.

An annual symposium in which drug company researchers disclose potential new medicines for the first time has become a tradition at spring American Chemical Society national meetings, and 2005 was no exception. Researchers revealed potential new medicines for thrombosis, anxiety, diabetes and cancer.

1,132 companies showcased thousands of analytical instruments and laboratory products in 2,474 exhibits booths, and the technical program featured 2,433 scientific presentations at the Pittcon 2005, Pittsburgh Conference & Exposition on Analytical Chemistry & Applied Spectroscopy. The number of exhibitors fell 5% from 2004, and the number of booths was down by 9%.

Several important advances made in 2004 in areas ranging from biochemistry and drug research to nanotech and inorganic chemistry, have been presented. These developments signify major strides toward attaining a better understanding of the chemical and biological world, and indicate novel applications of that knowledge in the future.

Complaints regarding combinatorial chemistry (combichem), the rapid synthesis and screening of collections of varied compounds to identify agents with desired functional properties, has not lived up to its hype as a speedy and prolific source of new biologically active agents and drugs. Combichems potential rescuer is diversity-oriented synthesis (DOS), and the synthesis of relatively small libraries of organic molecules that are structurally more complex, have a greater variety of core structures, and posses richer stereochemical variation than those produced by traditional combichem.

A new exhibit, 'Joseph Priestley, Radical Thinker,' had its grand opening at Chemical Heritage Foundation (CHF) in which CHF President Arnold Thackray presented each awardee with a miniature of this Priestley portrait. The CHF exhibit includes narrative descriptions about Priestley's life and relationship with his contemporaries and many Priestley-associated objects from CHF's own collection and others.

Researchers have developed novel chemical and enzymatic techniques for constructing oligosaccharides conveniently. These synthetic techniques are making it potential to envision a new generation of carbohydrate-based vaccines.

Different discussions and debates on a set of provocative and controversial drug discovery issues were held at the conference by the researchers. The meeting was held to address very complex issues, including perspectives on the range of chemistry relevant to biology and issues involving academia and the drug industry.

Pharmaceutical companies are assessing their drugs for toxicology at an early stage so that the drugs could be modified thereby not resulting in their withdrawal after their launch in the market. Nicholas A. Meanwell, director of Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford informed that liver toxicity was the major cause of withdrawal of drugs from the market between the years 1960 and 1999, accounting for 26% of 121 drugs withdrawn worldwide.

The 55th Pittsburgh Conference on Analytical Chemistry & Applied Spectroscopy in 2004, one of the world's premier instrument shows, indicated an improved business climate for the instrument makers and a number of innovative new products, particularly in the vibrational spectroscopy and chromatography areas. The number of conferees rose almost 20% over 2003.

Several scientists believe that transition-state binding and stabilization are primarily responsible for catalytic rate acceleration. Researchers are studying this phenomenon that may accompany or even supersede transition-state stabilization, where some suggest that catalysis in enzymes is accompanied by tunneling or electrostatistics, coupling protein and near-attack conformations.

Awards are given to significant contributions made in chemistry, F . Albert Cotton award in Synthethic Inorganic Chemistry to John E. Ellis , Distiguished Service in the Advancement of Inorganic Chemistry to James H. Espenson, Creative Advances in Enviromental science & Technology to Barbara J. Finlayson-Pitts, Glenn T. Seaborg award for Nuclear Chemistry to Donald G. Fleming, Creative Work in Synthetic Organic Chemistry to Tohru Fukuyama, Francis P. Garvan- James M. Olin Medal to Sandra C. Greer,James T. Grady-James H. Stack Award for Interpreting Chemistry for the Public to William s. Hammack, Ralph f. Hirschmann Awoard in Peptide Chemistry to Richard A. Houghten, Award for Volunteer Service to the American society to Valerie J. Kuck, Ipatieff Prize To Raul F. Lobo.

This extensive article provides an overview of how combinatorial chemistry (the synthesis of chemical compounds) has improved the discovery rate of valuable drugs, catalysts, and other useful compounds and materials. The article also describes criticism leveled at this field for its slowness in producing results.

This article describes efforts by chemists to understand and predict the folding of proteins. Many of these advances have occurred in the past seven years with the help of new technology, according to the many chemists interviewed for this article.

This article provides a detailed historical overview of the combinatorial chemistry industry. Initially, the industry was concerned with symthesing and characterizing collections of compounds and screening them for useful properties. The article discusses recent changes within the industry.

Muthiah Manoharan stated that currently between 30,000 and 40,000 genes have been identified. With these words, he opened a symposium on genes. Though the functions of all these genes are still not fully known, the opportunities for significant discovers in the drug industry are significant. One aspect of this research is target validation (verifying the medial significance of proteins).

The article discusses the first disclosures of clinical candidates, which reveal the development of new treatments for cancers, inflammatory diseases, and diabetic conditions.

The article discusses proteomics, which represents the next major development stage in understanding the mechanisms of life, following the completion of the Human Genome Project. Chemists feel they can play a significant role in proteomics.

Research chemists at Stanford University have released a new study of one of the simplest chemical reactions, the hydrogen-exchange reaction. The study, which is the result of a collaboration between theoreticians and experimentalists, demonstrates that the process is actually very complicated and difficult to understand.

Scripps Research Institute has developed 'click chemistry' strategy whereby reactive molecular building blocks are designed to 'click' together selectively and covalently. The possible resulting products include biological inhibitors and molecular-electronics components and many others.

The article examines new developments made in the chemical industry in 2001, particularly in the fields of organic chemistry, genomics, biochemistry, nanotechnology, and catalysis.

Industry analysts said that genomics, which is best known for the sequencing of the human genome, is making great progress in many areas. Researchers are focusing on analyzing single-nucleotide polymorphisms to understand the causes of cancer and other diseases.

Researchers looking into preventing AIDS disease are using enzyme inhibitors and discovering new antiinfective agents to fight AIDS.

Researchers are studying a method for treating cancer and heart disease which uses compounds that inhibit or activate adenosine A3 receptors. The research, which is being conducted in Italy and the United States, has targeted these cell-membrane proteins for the potential development of new drugs.

A review of top media stories on chemical research in 2000 covers topics such as chemical synthesis and chemical genomics. Other topics include structural biochemistry, drug research and nanomaterials.

Advances in multivalency could have an impact on new drug design in the future.

New technologies used by academic biochemists and various biotechnology companies in their cellular protein research efforts are discussed. Additional information on proteomics research tools is also included.

Alfred L. Goldberg of Harvard Medical School and other scientists are working with proteasomes in developing a new model for protein processing. They have also discovered a highly selective inhibitor and clinically tested two proteasome-inhibitor drugs.